MedTrace Logo

CASTRO-B - Study on CRP Apheresis in STROke Patients in Berlin

NCT03884153 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-03-25

No results posted yet for this study

Summary

This study explores the use of CRP level reduction in patients after suffering from acute ischemic stroke. Using selective CRP-apheresis, the investigators aim to reduce the secondary inflammatory tissue damage in the course of infarction maturation using infarction growth in MRI as the primary outcome as a surrogate.

Conditions

  • Stroke, Ischemic

Interventions

DEVICE

CRP apheresis

selective CRP apheresis by use of the "PentraSorb"-CRP

Sponsors & Collaborators

  • NeuroCure Clinical Research Center, Charite, Berlin

    collaborator OTHER

  • Department of Nephrology and Internal Intensive Care Medicine, Charite, Berlin

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Principal Investigators

  • Andreas Meisel, Prof. Dr. med. · Charite University, Berlin, Germany

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-03
Primary Completion
2022-08-30
Completion
2022-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03884153 on ClinicalTrials.gov